Overview

AnaptysBio is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. We are developing immune cell modulating antibodies, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases: rosnilimab, our PD-1 agonist, in a planned Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; and ANB032, our BTLA agonist, in a planned Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis. Our preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody for the treatment of autoimmune and inflammatory diseases.

AnaptysBio has developed two cytokine antagonists available for outlicensing: imsidolimab, an anti-IL-36r antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist that is Phase 2/3 ready. AnaptysBio has also discovered antibodies licensed to GSK in a financial collaboration for immune-oncology, including an anti-PD-1 antagonist (JEMPERLI (dostarlimab-gxly)), an anti-TIM-3 antagonist (cobolimab, GSK4069889) and an anti-LAG-3 antagonist (GSK4074386).

Strategy

Advancing our lead wholly owned programs for the treatment of severe inflammatory disease

We are developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory disease: rosnilimab, our PD-1 agonist program; and ANB032, our BTLA agonist program, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

We recently announced the advancement of –

  • Rosnilimab, our PD-1 agonist program, into a global Phase 2b trial to treat rheumatoid arthritis with study initiation in Q3 2023
  • ANB032, our BTLA agonist program, into a global Phase 2b trial to treat atopic dermatitis with study initiation in Q2 2023

Continuing imsidolimab development in GPP and outlicensing plans for legacy cytokine antagonist programs

We are advancing imsidolimab, our anti-IL-36r antibody, for the treatment of generalized pustular psoriasis (GPP), and we are planning to outlicense imsidolimab prior to potential FDA approval.

Etokimab, our anti-IL-33 antagonist antibody, is Phase 2/3-ready for the treatment of respiratory disorders and is available for outlicensing.

Identifying emerging target biology opportunities in inflammation and expanding our proprietary pipeline by generating new antibody product candidates using our technology platform

We intend to remain at the forefront of discovery and development of new therapeutic opportunities in inflammation by understanding and translating biological breakthroughs into first-in-class therapeutic antibodies. Our approach includes assessment of human genetics and tissue pathology to understand the relevance of emerging targets to patients with unmet medical needs. We plan to leverage this knowledge to create new product candidates and position our current and future programs for rapid clinical proof-of-concept achievement. Using our proprietary antibody generation platform, we are able to rapidly develop novel therapeutic antibodies against emerging targets. Our goal is to advance multiple additional wholly owned new therapeutic antibody program to IND submission.

Retaining rights to strategic products in key commercial markets

We intend to retain ownership and control of our pipeline programs to key inflection points. We may build sales and marketing capabilities in selected specialty markets that we believe can be served with a focused commercial organization. For certain programs, we plan to seek strategic collaborations that provide us with funding, infrastructure and marketing resources to advance through development and commercialization. 

Senior Leadership Team

Angela Stambaugh

Angela Stambaugh

Vice President, Program Management
Ben Stone

Ben Stone

Senior Vice President, Corporate Development
Beth Mueller

Beth Mueller

Senior Vice President, Human Resources
Daniel Faga

Daniel Faga

Interim President & CEO
Dennis Mulroy

Dennis Mulroy

Chief Financial Officer
Eric Loumeau

Eric Loumeau

Chief Operating Officer
Jihao Zhou, M.D., Ph.D.

Jihao Zhou, M.D., Ph.D.

Vice President, Data Sciences
Kenneth Luu, Ph.D.

Kenneth Luu, Ph.D.

Vice President, Clinical Pharmacology
Lewis Gryziewicz, PharmD

Lewis Gryziewicz, PharmD

Vice President, Regulatory Affairs
Martin Dahl, Ph.D.

Martin Dahl, Ph.D.

Senior Vice President, Research
Pejman Soroosh, Ph.D.

Pejman Soroosh, Ph.D.

Vice President, Immunology
Priya Raina

Priya Raina

Vice President, Clinical Operations
Stephen Parmley, Ph.D.

Stephen Parmley, Ph.D.

Vice President, Target Biology

Spotlight on Medical & Clinical Development Expertise

Bruce Randazzo, M.D., Ph.D., FAAD

Bruce Randazzo, M.D., Ph.D., FAAD

Vice President, Clinical Development
Cailin Sibley, M.D., MHS, FACR

Cailin Sibley, M.D., MHS, FACR

Vice President, Translational Medicine
Jocelyne Papacharalambous, M.D., MPH

Jocelyne Papacharalambous, M.D., MPH

Executive Medical Director, Medical Development

Board Of Directors

Daniel Faga

Interim President & CEO

Mr. Faga is a seasoned executive with more than 20 years of industry and advisory experience in the life sciences industry. Most recently, he was the chief operating officer at Mirati Therapeutics responsible for leading the company’s strategy, corporate finance, legal and other business operations.

+

Dennis Fenton, Ph.D.

Former Executive Vice President, Amgen

Dr. Fenton held positions of increasing responsibility at Amgen from 1982 through to his retirement in 2008, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and Executive Vice President.

+

Laura J. Hamill

Former Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences

Laura J. Hamill joined our Board of Directors in September 2019. Ms. Hamill has extensive experience in the biopharmaceutical industry, with over 30 years of global commercial experience in a variety of executive leadership positions.

+

Magda Marquet, Ph.D.

Co-founder of Althea Technologies, AltheaDx and ALMA Life Sciences, LLC

Dr. Magda Marquet joined our Board of Directors in January 2021. She was the co-CEO of Althea Technologies from 2000 to 2008. She is currently the co-CEO of Alma Life Sciences. LLC, an investment and consulting firm and serves on several Boards of Directors.

+

Oleg Nodelman

Founder and Portfolio Manager of EcoR1 Capital LLC

Oleg Nodelman joined our Board of Directors in April 2021. He is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm established in 2013, and has nearly twenty years of experience in biotech investing.

+

Hollings Renton

Former President and CEO of Onyx Pharmaceuticals

Hollings Renton has previously served as the Chief Executive Officer and President of Onyx Pharmaceuticals from 1993 to 2008 and as the Chairman of the Board from 2000 to 2008.

+

John Schmid

Former CFO of Auspex Pharmaceuticals

John Schmid has over 35 years of experience in financial and senior management in the biotech industry and has raised over $900 million in private and public equity as well debt financings as a Chief Financial Officer.

+

James N. Topper, M.D., Ph.D.

Chairman of AnaptysBio
Managing General Partner at Frazier Healthcare

Jamie Topper, M.D., Ph.D., is a Managing General Partner of Frazier Healthcare Partner’s Life Sciences team. He joined Frazier in 2003 and opened Frazier’s Menlo Park office in the same year. Throughout his 11 years as a General Partner, Dr. Topper has invested across over 20 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies.

+

J. Anthony Ware, M.D.

Former SVP Product Development, Lilly Bio-Medicines, Eli Lilly and Company

Dr. Ware served as the Senior Vice President of Product Development of Lilly Bio-Medicines at Eli Lilly and Company, where he was responsible for the clinical development and regulatory approval of new medicines in multiple therapeutic areas.

+

Scientific Advisory Board

Michael Gallatin, Ph.D.

Former Vice President and Scientific Director of ICOS Corporation

Michael Gallatin, Ph.D., is a former Vice President and Scientific Director of ICOS Corporation, where his responsibilities included discovery, preclinical research, medicinal chemistry and process chemistry groups, including those responsible for worldwide development and launch of Tadalafil (Cialis®).

+

Christopher Hunter, Ph.D.

Mindy Halikman Heyer President’s Distinguished Chair and former chair of the Department of Pathobiology at the University of Pennsylvania School of Veterinary Medicine

Christopher Hunter, Ph.D. is the Mindy Halikman Heyer President’s Distinguished Chair and former chair of the Department of Pathobiology at the University of Pennsylvania School of Veterinary Medicine. Dr. Hunter’s research has focused on the host’s immune response to infections and the innate events that lead to the development of long term protective immunity mediated […]

+

John G. Monroe, Ph.D.

Emeritus Professor, University of Pennsylvania School of Medicine

John G. Monroe, Ph.D., is an Emeritus Professor at the Perelman School of Medicine at the University of Pennsylvania. He is a former Senior Director at Genentech where he led the Immunology Discovery Department that is responsible for new target discovery and pre-clinical validation.

+

Luisa Salter-Cid, PH.D.

Chief Scientific Officer, Pioneering Medicines and Board Member Jounce Therapeutics

Luisa Salter-Cid, Ph.D. is the current Chief Scientific Officer at Pioneering Medicines, Flagship Pioneering and has been serving on the board of directors for Jounce Therapeutics since February 2021. Throughout her career Dr. Salter-Cid has authored of over 70 publications and patents.

+

Contact

AnaptysBio, Inc.

10770 Wateridge Circle
Suite 210
San Diego, CA 92121-5801

 

Phone: (858) 362-6295
Fax: (858) 362-6296
info@anaptysbio.com

General Information

info@anaptysbio.com

Job Opportunities

Please see our Job Openings page.